CLINICAL_TRIALS
trial_result
· 2017-01-19
Clinical Trial Update: Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients [Phase 3]
Summary
A Phase 3 pediatric trial evaluated romiplostim for safety and efficacy in immune thrombocytopenia, with results posted in January 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Idiopathic Thrombocytopenic Purpura, Thrombocytopenia | Phase 3 | Status: COMPLETED | Results posted: 2017-01-19